When Do Medical Marijuana Dispensaries Open In Oklahoma?
The cannabis laws are still very new to Oklahoma. We are estimating that it could be later this year, November or December, by the time the growers and producers will have their products available to supply dispensaries around Oklahoma. With the current legislation not in place it could be 2019.
It all depends on what happens with the law. If unforeseen roadblocks occur, it could be next year before any dispensaries have products to offer.
Medical Marijuana Dispensary Oklahoma City
Since the legalization of marijuana in the state of Oklahoma, there have been many dispensaries to choose from, and it has become a huge market statewide. And with all of the optional places to make your next medical marijuana purchase, how do you choose the best location? When looking for a marijuana dispensary, you want to find a location that is convenient, purchase from someone who knows about marijuana, and you want the opportunity to choose from as many products as possible.
You have the choice to go anywhere to buy your medical or recreational marijuana, but you don’t want to go to just any dispensary in Oklahoma City. Choose a dispensary that has everything you need in one location. For the best dispensary, you will want to go to URBN Lotus.
Cannabis. Cannabis is the preferred designation of the plant Cannabis sativa, Cannabis indica, and of minor significance, Cannabis ruderalis.
1 According to the 1961 United Nations Single Convention on Narcotic Drugs, cannabis is defined as “the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated.”
2 Cannabis resin means “separated resin, whether crude or purified, obtained from the cannabis plant”. These definitions are narrower than the botanical definition and as a consequence, certain parts of the plant are not under international control. The term cannabis will be used instead of marijuana, or other names indigenous to local cultures, unless there is a need to refer to a specific phrase, e.g. medical marijuana ballot initiatives. Its use for medicinal, ritual or recreational purposes results from the actions of cannabinoids in the cannabis plant. These compounds also produce the unintended adverse consequences of cannabis. Cannabinoids.Cannabinoids are basically derived from three sources: (a) Phytocannabinoids are cannabinoid compounds produced by plants Cannabis sativa or Cannabis indica; (b) Endocannabinoids are neurotransmitters produced in the brain or in peripheral tissues, and act on cannabinoid receptors; (c) Synthetic cannabinoids, synthesized in the laboratory, are structurally analogous to phytocannabinoids or endocannabinoids and act by similar biological mechanisms.
Medical Marijuana – A Historical Perspective
• Use dates back 12,000 years
• Started in central Asia and flourished in Southeast Asia and India
• 600 BCE: Earliest medical description of cannabis in Shennong Ben Cao Jin, compiled circa 100 CE from earlier oral traditions. Earliest archeological evidence of cannabis use dates to 600 BCE in Yanghai, China.
• Ancient China: malaria, constipation, rheumatic pain, female reproductive disorders
• Ancient India: euphoric properties [2000 BC], religious sacrament, fever reduction, promoting sleep, stimulating appetite, relieving headaches, curing VDs
• Azerbaijan: reports of medical marijuana in 9th century AD
• Introduced into the Americas in 1600s by English settlers and Spanish conquistadors
• 1616: Jamestown cultivates Cannabis sativa for hemp fibers
• 1842: O’Shaughnessy, a British army physician in India, produced a review of the use of cannabis in the treatment of various medical conditions
• Listed in the U.S. Pharmacopeia from 1850 – 1942
• Recreational use began to surge in 1930s during prohibition
• 1937: Marijuana Tax Act taxed and criminalized sale of marijuana. Medical use technically legal, but discouraged by taxes and regulations
• 1970: Controlled Substances Act places cannabis in Schedule I [high abuse liability, NO therapeutic potential]
• C. sativa, C. indica, and C. Ruderalis
• Often characterized by sativa having a “head” high vs. indica having a “body” high – not very accurate (McPartland, 2014)
• Hybrids dominate the market
• Cultivar names often mean little; instead rely on chemical profile
• Blocks formation of 11-OH-THC
• Non-competitive antagonist of CB-1
• Inverse agonist of CB-2
• Inhibits the reuptake and degradation of anandamide
• Little affinity for CB-1 and CB-2 receptors [100 fold less than THC]
• Antagonist at 5-HT1A receptor – possible antidepressant, anti-anxiety and procognitive effects
• May counteract effects of THC [anxiety, tachycardia, panic attacks, psychosis] while enhancing therapeutic efficacy [Izzo 2009, Russell 2011]